Indivior (LON:INDV) Receives Buy Rating from Jefferies Financial Group

Indivior (LON:INDV)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a research note issued to investors on Tuesday,Digital Look reports. They currently have a GBX 1,800 ($22.84) target price on the specialty pharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 93.13% from the stock’s current price.

Separately, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,500 ($19.03) price target on shares of Indivior in a report on Thursday, September 5th.

Indivior Trading Down 1.9 %

LON INDV traded down GBX 18 ($0.23) on Tuesday, hitting GBX 932 ($11.82). 322,011 shares of the stock were exchanged, compared to its average volume of 1,124,100. Indivior has a 52-week low of GBX 554.50 ($7.04) and a 52-week high of GBX 1,770 ($22.46). The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.85. The stock has a fifty day moving average price of GBX 768.84 and a two-hundred day moving average price of GBX 923.78. The firm has a market capitalization of £1.20 billion, a P/E ratio of -1,166.25, a P/E/G ratio of -5.57 and a beta of 0.19.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.